These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

7045 related articles for article (PubMed ID: 22822590)

  • 41. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Left Ventricular Dysfunction After Treatment With Ipilimumab for Metastatic Melanoma.
    Roth ME; Muluneh B; Jensen BC; Madamanchi C; Lee CB
    Am J Ther; 2016; 23(6):e1925-e1928. PubMed ID: 26885708
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
    Simeone E; Ascierto PA
    J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
    Lynch TJ; Bondarenko I; Luft A; Serwatowski P; Barlesi F; Chacko R; Sebastian M; Neal J; Lu H; Cuillerot JM; Reck M
    J Clin Oncol; 2012 Jun; 30(17):2046-54. PubMed ID: 22547592
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Upcoming strategies for the treatment of metastatic melanoma.
    Spagnolo F; Queirolo P
    Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
    Juszczak A; Gupta A; Karavitaki N; Middleton MR; Grossman AB
    Eur J Endocrinol; 2012 Jul; 167(1):1-5. PubMed ID: 22495490
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients.
    Konstantinou MP; Dutriaux C; Gaudy-Marqueste C; Mortier L; Bedane C; Girard C; Thellier S; Jouary T; Grob JJ; Richard MA; Templier C; Sakji L; Guillot B; Paul C; Meyer N
    Acta Derm Venereol; 2014 Jan; 94(1):45-9. PubMed ID: 23824275
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Orbital myositis associated with ipilimumab].
    Lecouflet M; Verschoore M; Giard C; Gohier P; Le Corre Y; Milea D; Martin L
    Ann Dermatol Venereol; 2013; 140(6-7):448-51. PubMed ID: 23773743
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ipilimumab for advanced melanoma: a pharmacologic perspective.
    Trinh VA; Hagen B
    J Oncol Pharm Pract; 2013 Sep; 19(3):195-201. PubMed ID: 23047236
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma.
    Sherrill B; Wang J; Kotapati S; Chin K
    Br J Cancer; 2013 Jul; 109(1):8-13. PubMed ID: 23787916
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial.
    Weber JS; Amin A; Minor D; Siegel J; Berman D; O'Day SJ
    Melanoma Res; 2011 Dec; 21(6):530-4. PubMed ID: 22051508
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neurological immune-related adverse events of ipilimumab.
    Bot I; Blank CU; Boogerd W; Brandsma D
    Pract Neurol; 2013 Aug; 13(4):278-80. PubMed ID: 23487828
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma.
    Lee D; Porter J; Hertel N; Hatswell AJ; Briggs A
    BioDrugs; 2016 Aug; 30(4):307-19. PubMed ID: 27177756
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ipilimumab-Induced Granulomatous Disease Occurring Simultaneously With Disease Progression in a Patient With Metastatic Melanoma.
    Toumeh A; Sakhi R; Shah S; Arudra SK; De Las Casas LE; Skeel RT
    Am J Ther; 2016; 23(4):e1068-71. PubMed ID: 25933140
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports.
    Marlier J; Cocquyt V; Brochez L; Van Belle S; Kruse V
    Endocrine; 2014 Dec; 47(3):878-83. PubMed ID: 24554495
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma.
    Feng Y; Roy A; Masson E; Chen TT; Humphrey R; Weber JS
    Clin Cancer Res; 2013 Jul; 19(14):3977-86. PubMed ID: 23741070
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma.
    Albarel F; Gaudy C; Castinetti F; Carré T; Morange I; Conte-Devolx B; Grob JJ; Brue T
    Eur J Endocrinol; 2015 Feb; 172(2):195-204. PubMed ID: 25416723
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ipilimumab (Yervoy) and inoperable or metastatic melanoma. More evaluation needed, in both first- and second-line use.
    Prescrire Int; 2015 Apr; 24(159):96. PubMed ID: 25941700
    [No Abstract]   [Full Text] [Related]  

  • 59. Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review.
    Kopecký J; Trojanová P; Kubeček O; Kopecký O
    Jpn J Clin Oncol; 2015 Apr; 45(4):381-4. PubMed ID: 25583422
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Unusual pulmonary toxicity of ipilimumab treated by macrolides.
    Mailleux M; Cornélis F; Colin GC; Baurain JF
    Acta Clin Belg; 2015 Dec; 70(6):442-4. PubMed ID: 26790556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 353.